RSUME与垂体腺瘤侵袭性的分子机制研究进展  

Research Progress in molecular mechanisms between RSUME and invasive pituitary adenoma

作　　者：何伟[1] 王大鹏[1] 沈晓黎[1] 

机构地区：[1]南昌大学第二附属医院神经外科,南昌市330006

出　　处：《中国肿瘤临床》2014年第14期942-944,共3页Chinese Journal of Clinical Oncology

摘　　要：垂体腺瘤为颅内良性肿瘤,但却是成年人脑肿瘤的第三大常见肿瘤,仅次于神经胶质瘤和脑膜瘤。垂体腺瘤定义为良性肿瘤,但部分垂体腺瘤可对周围组织有侵袭性,手术难以切除,术后易复发。RWD结构修饰增强子(RWD containing su-moylation enhancer,RSUME),可在垂体腺瘤中通过小泛素化(small ubiquitin related modifiers,SUMO)稳定缺氧诱导因子-1α(hy-poxia inducible factor-1α,HIF-1α)以及抑制分子kappaB(inhibitor kappaB,IκB)的活性,促进垂体腺瘤的侵袭作用。RSUME对垂体腺瘤的侵袭性起着重要的作用,但RSUME的作用与垂体腺瘤侵袭的相关性尚未明确。本文就RSUME对垂体腺瘤侵袭作用中HIF-1α/VEGF信号通路以及IκB/NF-κB复合体的作用进行综述。Pituitary adenoma, a benign intracranial tumor, is the third most common brain tumor, second only to glioma and meningioma. Pituitary adenoma has been defined as a benign tumor, but some pituitary adenomas can invade the surrounding tissue. This tumor is difficult to resect and can easily recur after surgery. RWD-containing sumoylation enhancer （RSUME） can stabilize the activity of hypoxia-inducible factor-1α and inhibitor kappaB by the small ubiquitin-related modifiers. This phenomenon indicates the impor-tance of RSUME in pituitary adenoma because it promotes the invasiveness of the tumor. However, the correlation between RSUME and the invasion of pituitary adenoma remains unclear. In this study, the roles of RSUME on HIF-1α/VEGF signaling pathway and IκB/NF-κB compomers in the invasiveness of pituitary adenoma were reviewed.

关 键 词：RSUME 垂体腺瘤 侵袭性分子机制 

分 类 号：R736.4[医药卫生—肿瘤]